Recent Updates
Recently added Catalysts
GERN

Geron to Present at the Cantor Fitzgerald Healthcare Conference

Key Takeaway: MENLO PARK, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m. Easter

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
4.4%
average across 4 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
Imetelstat
Phase 3 · Myelofibrosis

Full Press Release Details

MENLO PARK, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m. Eastern Time on Tuesday, September 26, 2017.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/cantor6/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Anna Krassowska, Ph.D.
Investor and Media Relations
Last updated: Sep 19, 2017